Your Messages Inbox
Your Article Summary
See Latest ArticlesAmgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor Blockers
Amgen, 08/05/09
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, issued a statement in response to the Food and Drug Administration announcement regarding the results of a safety review of Tumor Necrosis Factor blockers. This safety review was the subject of an FDA Early Communication in June 2008 pertaining to cases of malignancy in pediatric patients exposed to a TNF blocker. As a result of this review, the FDA has required strengthened warnings about the occurrence of lymphoma and other cancers in children and young adults using these medicines.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Watson Files FDA Application for Generic Rozerem
Watson Pharmaceuticals, 12/07/09
Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
Bristol Myers-Squibb Company, 12/07/09
Non-safety-related voluntary recall of a limited portion of Daytrana (methylphenidate transdermal system) patches announced
Shire, 12/07/09
Article Search
Sponsor